Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stapled intracellular-targeting antimicrobial peptides to treat infection

a technology of antimicrobial peptides and intracellular targeting, which is applied in the direction of antibacterial agents, peptide sources, peptide/protein ingredients, etc., can solve the problems of increasing antibiotic discovery burden, falling antibiotic discovery burden on academic research centers and hospitals, and increasing antibiotic resistance, so as to enhance antimicrobial activity and import the effect of little to no off-target toxicity and little to no toxicity

Inactive Publication Date: 2017-08-31
DANA FARBER CANCER INST INC
View PDF2 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent describes a way to make compounds that have strong antimicrobial properties but are not likely to harm other living cells. This is done by adding a hydrocarbon staple to certain sequences of peptides, which helps to stabilize their structure and make them resistant to breakdown in the body. The stapled peptides also have a reduced ability to kill or inhibit the growth of microbial cells. This approach could lead to new treatments for bacterial infections that are effective and safe.

Problems solved by technology

The rise of antibiotic superbugs is a major threat to healthcare systems around the globe.
In addition, due to the regulatory hurdles and low financial incentive for pharmaceutical and biotechnology companies to invest in antibiotic research, the burden of antibiotic discovery has fallen to academic research centers and hospitals [5-6].
Traditional drug discovery technologies have served us well this far; however, as bacterial resistance has evolved over time, these technologies have become increasingly obsolete.
Nonetheless, much development and research needs to be done before such therapeutics could reach the bedside of patients who need novel antibiotics urgently.
While much focus has been levied onto certain α-helical AMPs due to their membrane lytic properties and the vast amount of structural and mechanistic data available, other families of AMPs have remained much less studied and characterized.
However, it has been difficult to characterize these AMPs properly, since at high concentrations, most AMPs become lytic and current model membrane systems are too simplistic [8].
Nevertheless, the generally poor stability and low potency of I-TAMPs, including buforin II, have reduced interest in further development of buforin II and / or other I-TAMPs as active pharmaceutical agents and have led to their being generally relegated to use as research reagents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stapled intracellular-targeting antimicrobial peptides to treat infection
  • Stapled intracellular-targeting antimicrobial peptides to treat infection
  • Stapled intracellular-targeting antimicrobial peptides to treat infection

Examples

Experimental program
Comparison scheme
Effect test

example 1

of Stapled I-TAMP Analogues

[0432]We synthesized a complete i, i+4, and 1, i+7 staple scanning panel of stapled buforin II peptides to identify which staple insertion position(s) yield I-TAMP analogues with optimal biological and pharmacologic properties (FIG. 1). In some compositions, replacement of the central proline residue was avoided given the potential role of prolines as breakpoints in secondary structure. Also, in some panels, the phenylalanine adjacent to the proline was replaced with tryptophan for facile determination of peptide concentration by UV spectroscopy. The production of these exemplary panels allowed us to interrogate the effects of structural stabilization of various segments of the parent I-TAMP on its antimicrobial and hemolytic activity.

example 2

ical Characterization of Stapled I-TAMP Analogues

[0433]To determine the α-helical content for each peptide within our panel of stapled I-TAMP analogues, we studied the peptides dissolved in 10 mM phosphate buffer (pH 7.4) using CD spectroscopy in the presence and absence of trifluoroethanol (TFE; 50% v / v), an α-helix promoting solvent. In the absence of TFE, the i, i+4 stapled analogues displayed modestly improved α-helical structure compared to the unstapled parent I-TAMP, buforin II (F10W), which was otherwise completely disordered (FIG. 2 Panel A). Upon the addition of TFE, the α-helical content increased for some of the stapled analogues and the parent I-TAMP (F10W), but not as dramatically as we previously observed for α-helical AMPs (FIG. 2 Panel B), consistent with the incorporation of a helix-breaking proline within the buforin II sequence. The i, i+7 stapled analogues displayed higher levels of α-helicity when compared to their i, i+4 counterparts, both in the presence and ...

example 3

Activity of Stapled I-TAMP Peptides

[0434]One of the key obstacles that have long impeded the use of AMPs in systemic infections such as sepsis is their tendency to lyse human cells, such as red blood cells (RBCs). Thus, it is critical to minimize hemolytic activity as much as possible to achieve a therapeutic window. When we tested stapled analogues of the I-TAMP buforin II in a 1% RBC suspension in phosphate buffer, most i, i+4 analogues displayed low hemolytic activity, although in some cases there was a 5-fold increase in hemolysis (TABLE 1). Generally, the i, i+7 analogues had higher hemolytic activity, likely due to the greater hydrophobicity of the longer hydrocarbon staple (Table 1). Of note, in those circumstances where hydrocarbon staples increase hemolytic activity due to increasing hydrophobicity, the alkene moiety can be modified, e.g., by dihydroxylation, to install hydrophilic residues and potentially mitigate hemolysis.

[0435]Balancing antimicrobial potency and suppres...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

Structurally stabilized, e.g., stapled, peptides with the ability to translocate through microbial cell membranes to the interior of microbial cells and exert a biological activity there are provided, as are methods of designing, making and using such peptides.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 62 / 301,426, filed Feb. 29, 2016, the content of which is incorporated herein by reference in its entirety.TECHNICAL FIELD[0002]This disclosure relates to structural stabilization of intracellular-targeting antimicrobial peptides and methods for using such peptides to treat bacterial and other pathogenic infections.BACKGROUND OF THE INVENTION[0003]The rise of antibiotic superbugs is a major threat to healthcare systems around the globe. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that healthcare costs due to antibiotic-resistant infections amount to $20 billion per year [1]. With the antibiotic pipeline drying up over the past decade, there are very few drug candidates to restock our antibiotic arsenal to address resistant infections [2-4]. In addition, due to the regulatory hurdles and low financial incentive for pharmace...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/46A61K45/06C07K14/435C07K14/47A61K38/08C07K7/08A61K38/10A61K38/17C07K7/06
CPCC07K14/461A61K38/1706A61K45/06C07K14/43504A61K38/1767C07K14/463A61K38/1709C07K7/06A61K38/08C07K7/08A61K38/10C07K14/47A61K38/1703A61P31/04A61P43/00Y02A50/30
Inventor WALENSKY, LOREN D.MOURTADA, RIDA
Owner DANA FARBER CANCER INST INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com